Therapeutic antibodies for autoimmunity and inflammation - PubMed

Affiliations

• PMID: 20414204
• DOI: 10.1038/nri2761

Review

Therapeutic antibodies for autoimmunity and inflammation

Andrew C Chan et al. Nat Rev Immunol. 2010 May.

Abstract

The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.

Similar articles

• A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.

  Lyman M, Lieuw V, Richardson R, Timmer A, Stewart C, Granger S, Woods R, Silacci M, Grabulovski D, Newman R. Lyman M, et al. J Biol Chem. 2018 Jun 15;293(24):9326-9334. doi: 10.1074/jbc.M117.818559. Epub 2018 Apr 20. J Biol Chem. 2018. PMID: 29678878 Free PMC article.

• Strategies and challenges for the next generation of therapeutic antibodies.

  Beck A, Wurch T, Bailly C, Corvaia N. Beck A, et al. Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747. Nat Rev Immunol. 2010. PMID: 20414207 Review.

• Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date.

  Zhao Q. Zhao Q. BioDrugs. 2020 Apr;34(2):111-119. doi: 10.1007/s40259-019-00400-2. BioDrugs. 2020. PMID: 31916225 Review.

• The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE.

  Wang C, Pan HF, Ye DQ. Wang C, et al. Autoimmun Rev. 2012 Mar;11(5):373. doi: 10.1016/j.autrev.2011.01.002. Epub 2011 Jan 9. Autoimmun Rev. 2012. PMID: 21224014 No abstract available.

• [Biological response modifiers in the treatment of immunoinflammatory diseases].

  Skov L, Bendtzen K. Skov L, et al. Ugeskr Laeger. 2008 Jun 9;170(24):2120-6. Ugeskr Laeger. 2008. PMID: 18565292 Review. Danish.

Cited by

• Lymph node choreography: B cells take the lead.

  Cannons JL, Lu KT, Schwartzberg PL. Cannons JL, et al. Nat Immunol. 2012 Jun 19;13(7):630-2. doi: 10.1038/ni.2349. Nat Immunol. 2012. PMID: 22713820 No abstract available.

• The Structural Role of Antibody N-Glycosylation in Receptor Interactions.

  Subedi GP, Barb AW. Subedi GP, et al. Structure. 2015 Sep 1;23(9):1573-1583. doi: 10.1016/j.str.2015.06.015. Epub 2015 Jul 23. Structure. 2015. PMID: 26211613 Free PMC article.

• The clinical significance of allergen-specific IgG4 in allergic diseases.

  Qin L, Tang LF, Cheng L, Wang HY. Qin L, et al. Front Immunol. 2022 Oct 25;13:1032909. doi: 10.3389/fimmu.2022.1032909. eCollection 2022. Front Immunol. 2022. PMID: 36389804 Free PMC article. Review.

• Monoclonal antibodies in cancer therapy.

  Scott AM, Allison JP, Wolchok JD. Scott AM, et al. Cancer Immun. 2012;12:14. Epub 2012 May 1. Cancer Immun. 2012. PMID: 22896759 Free PMC article. Review. No abstract available.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal